A partial agonist of GPR109A/HCA2 receptors (Ki = 0.55 μM in a radioligand binding assay); stimulates [35S]-GTPγS binding and increases phosphorylation of ERK in HEK293T cells expressing GPR109A/HCA2 receptors (EC50s = 3.1 and 0.32 μM, respectively); reduces plasma levels of VLDL and hepatic expression of apolipoprotein B in mice at 400 mg/kg per day ,